Bausch Health Companies Inc   (BHC)
Other Ticker:  
Price: $8.9900 $-0.19 -2.070%
Day's High: $9.18 Week Perf: 4.53 %
Day's Low: $ 8.83 30 Day Perf: 11.26 %
Volume (M): 2,535 52 Wk High: $ 10.15
Volume (M$): $ 22,787 52 Wk Avg: $7.87
Open: $9.18 52 Wk Low: $5.57

 Market Capitalization (Millions $) 3,285
 Shares Outstanding (Millions) 365
 Employees 21,000
 Revenues (TTM) (Millions $) 8,757
 Net Income (TTM) (Millions $) -611
 Cash Flow (TTM) (Millions $) 371
 Capital Exp. (TTM) (Millions $) 272

Bausch Health Companies Inc
Bausch Health Companies Inc. (formerly known as Valeant Pharmaceuticals International Inc.) is a multinational pharmaceutical company that was founded in 1960 and is based in Laval, Canada. The company focuses on innovative pharmaceutical products and medical devices for the treatment of eye health, gastroenterology, dermatology, and aesthetics. Bausch Health operates in more than 100 countries, selling products to healthcare providers and patients around the world.

Bausch Health has a diverse portfolio of products, including prescription drugs, over-the-counter medications, contact lenses, surgical instruments, and biologic drugs. The company has a number of strong brands, including Bausch + Lomb, Salix Pharmaceuticals, and Ortho Dermatologics. Bausch + Lomb is a leading global eye health business that offers contact lenses, ocular drugs, and surgical instruments. Salix Pharmaceuticals is a specialized gastroenterology company that offers treatments for gastrointestinal diseases. Ortho Dermatologics offers prescription dermatology products.

Bausch Health is committed to research and development, spending significant resources on developing new products and improving existing ones. The company has a strong pipeline of products, and it invests heavily in clinical trials to ensure that its products are effective and safe.

Bausch Health has faced regulatory and legal challenges in the past, including allegations of accounting fraud and price gouging for some of its drugs. In response, the company has implemented a number of reforms, including changes to its governance structure and pricing policies.

Overall, Bausch Health Companies Inc. is a major player in the pharmaceutical industry, with a diverse portfolio of products and a strong commitment to research and development. The company has faced challenges in the past but has taken steps to improve its reputation and ensure that its products are accessible and affordable for patients.

   Company Address: 2150 St. Elzéar Blvd. West Laval 0 QC
   Company Phone Number: 744-6792   Stock Exchange / Ticker: NYSE BHC


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Bausch Health Companies Inc

Headline: Bausch Health Companies Inc Shows Resilience in Q3 2023 with Impressive Revenue Growth, Despite Financial Losses

In a time of uncertainty and fluctuation, the stock market can often feel like a turbulent rollercoaster ride. But amidst the ups and downs, there are companies that continue to strive for success and make impressive strides forward. One such company is Bausch Health Companies Inc, whose recent financial report for the third quarter of 2023 showcases their tenacity and determination in the face of challenges.
Despite an increase in revenue of 9.384% year on year, reaching $2.24 billion, Bausch Health Companies Inc unfortunately fell short of reaching break-even point, posting a loss per share of $-1.03. While this may seem disappointing on the surface, it's important to note that Bausch's revenue growth in the third quarter far surpassed their counterparts in the Major Pharmaceutical Preparations sector, who only experienced a 1.30% rise during the same time period. This is a testament to Bausch's ability to not only weather the storm but also outperform their competitors.

Bausch Health Companies Inc

Pharmaceutical Giant Bausch Health Skyrockets Profits in Q2 2023, Reports Impressive Fiscal Growth

Bausch Health Companies Inc, formerly known as Valeant Pharmaceuticals International, is a major player in the pharmaceutical industry. The company recently released its second-quarter earnings for 2023, showing a significant improvement in financial performance compared to the previous year.
In the second quarter of 2023, Bausch Health Companies Inc reported a positive earnings per share (EPS) of $0.07, compared to a loss per share of $-0.40 in the same period a year ago. The company's EPS also showed improvement from the preceding quarter, as it turned positive from $-0.55 per share. This turnaround in income is a positive sign for the company and indicates its ability to generate profits.

Bausch Health Companies Inc

Bausch Health Companies Inc. Exhibits Muted Growth in Top-line during Financial Period Ending March 31, 2023

Bausch Health Companies Inc. has recently reported their financial results for the quarter ending March 31, 2023. The company's diminishing returns increased to $-0.55 per share compared to $-0.19 from the previous year, indicating a decline in their financial performance over time. However, there was an improvement in earnings per share (EPS), which was $-1.13 per share from the prior quarter.
The company's revenue grew marginally by 1.356% to $1.94 billion from $1.92 billion in the corresponding quarter a year before. However, there was a significant decline in sequentially revenue by -11.354% from $2.19 billion. This suggests that the company's business operations are not performing as expected and indicates the need for improvement.


Bausch Health Companies Inc's Segments
• View Complete Report
  Company Estimates  
  Revenue Outlook
Bausch Health Companies Inc does not provide revenue guidance.

Earnings Outlook
Bausch Health Companies Inc does not provide earnings estimates.

Geographic Revenue Dispersion


About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com